Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06412562 tablets_Fasted · 1 trial · 1 indication
AUC (0 - inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time. It is obtained from AUC (0 - t) plus AUC (t - inf).
AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 3 mg PF-06412562 MR tablets_Fasted | DRUG | A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast |
| 2 x 15 mg PF-06412562 MR tablets_Fasted | DRUG | Two 15 mg PF-06412562 modified release tablets administered after an overnight fast |
| 2 x 15 mg PF-06412562 MR tablets_Fed | DRUG | Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast |
| 10 mg PF-06412562 IR tablets | DRUG | a single immediate release tablet of 10 mg PF-06412562 after an overnight fast |
Inclusion Criteria: * Healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse ...
PF-06412562 tablets_Fasted is an investigational small molecule being studied in healthy volunteers. It is being evaluated in a Phase 1 clinical trial to gain information about blood concentrations after oral administration of a modified release formulation in fasted and fed conditions. The drug is not approved and remains in clinical development.
PF-06412562 tablets_Fasted is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting a Phase 1 clinical trial of this investigational small molecule in healthy volunteers.
PF-06412562 tablets_Fasted is in Phase 1 clinical development. It is an investigational drug and has not been approved. One Phase 1 trial has been completed, with no active trials currently ongoing.
PF-06412562 tablets_Fasted has one completed clinical trial, NCT02201511, titled "A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions." This Phase 1 study enrolled 12 participants in Belgium.
PF-06412562 tablets_Fasted refers to the modified release tablet formulation of PF-06412562, which is being studied under fasted conditions. The trial NCT02201511 evaluates this formulation in healthy volunteers to assess blood concentrations after oral administration.